Show Summary Details
Page of

Frontotemporal dementias 

Frontotemporal dementias
Frontotemporal dementias

Lars Gustafson

and Arne Brun

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 June 2022

Nosological classification of organic dementia is based on current knowledge and theories of aetiology, including genetics, clinical picture, the pathological substrate, and the predominant location of brain damage. This chapter is concerned with dementia syndromes caused by a degenerative disease primarily affecting the frontal and temporal lobes, named frontal-lobe dementia or frontotemporal dementia (FTD). The terminology should be viewed from a historical perspective. The relationship between localized cortical atrophy in dementia and symptoms of aphasia was first reported by Pick in 1892. The pathological account of this lobar degeneration by Alzheimer in 1911 described ‘ballooned’ neurones (Pick cells) and argentophilic globes (Pick bodies), and the clinicopathological entity was named Pick's disease. In the 1980s, attention was drawn to a larger group of frontal-lobe dementias associated with frontotemporal cortical degeneration. The Lund–Manchester consensus of 1994 delineated the prototypical clinical syndrome of FTD with three neuropathological constituents, frontal lobe degeneration of non-Alzheimer type (FLD), (alternatively designated ‘dementia lacking distinctive histology’), Pick's disease, and motor neurone disease (MND) with dementia (FTD-MND). The 1998 consensus on clinical diagnostic criteria for frontotemporal lobar degeneration (FTLD) encompassed two additional dementia syndromes; progressive non-fluent aphasia (PA), and semantic dementia. Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) have also been associated with FTLD. A changing clinical classification is shown in Fig. The addition of important genetic and histochemical characteristics has further added to the complex classification of FTD and FTLD with a risk of developing numerous and partly competing definitions. FTLD may be further subclassified into forms positive or negative for tau and ubiquitin. The ubiquitinated form will be referred to as FTD-U, which is synonymous to FLTD-U.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.